EUVIMEDEUVIMED entdecken
Open Access

Anti‐ BCMA CAR ‐ NK Cells Reveal Enhanced Cytolytic and Secretory Responses Against Myeloma Cells

Bita Divsalar, Jaffar Kiani, Saeid Abroun, Masoud Soleimani iD

APMIS · 2026

DOI: 10.1111/apm.70256 ↗

Kurz gefasst

Fachartikel in der Zeitschrift APMIS, 2026. Verfasst von Bita Divsalar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University (TMU), Tehran, Iran. Hauptthemen laut MEDLINE: Multiple Myeloma, Killer Cells, Natural, B-Cell Maturation Antigen, Receptors, Chimeric Antigen. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Tarbiat Modares University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma (MM) is a hematologic malignancy characterized by uncontrolled malignant plasma cell proliferation. B‐cell maturation antigen (BCMA) is an attractive therapeutic target due to its high expression on malignant plasma cells. In this study, BCMA‐directed CAR‐NK‐92 cells were generated via lentiviral transduction of a second‐generation CAR construct. CAR expression was confirmed by flow cytometry (81% efficiency). Engineered cells were functionally evaluated against BCMA‐positive (U266, RPMI‐8226) myeloma cell lines, as well as BCMA‐negative control cells (K562, Jurkat). CAR‐NK‐92 cells demonstrated significantly enhanced cytotoxic activity against BCMA‐positive targets compared with parental NK‐92 cells (e.g., 87% vs. 54% cytotoxicity at 1:1, p < 0.001). Enhanced antitumor activity was accompanied by increased CD107α surface expression and elevated secretion of perforin, granzyme B, TNF‐α, and IFN‐γ ( p < 0.05). No significant differences in cytotoxicity or cytokine secretion were observed against BCMA‐negative control cells ( p > 0.05), supporting antigen‐specific activity. Importantly, CAR‐NK‐92 cells also exhibited potent cytotoxicity and significantly elevated cytokine secretion against primary CD138+ myeloma cells isolated from patient bone marrow aspirates. These findings demonstrate that anti‐BCMA CAR‐NK‐92 cells exhibit potent and selective antimyeloma activity in vitro, supporting CAR‐NK‐92 cells as an off‐the‐shelf immunotherapeutic platform for multiple myeloma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaKiller Cells, NaturalB-Cell Maturation AntigenReceptors, Chimeric AntigenCytotoxicity, ImmunologicImmunotherapy, AdoptiveHumansCell Line, TumorInterferon-gammaCytokines

Stichwörter der Autor:innen

BCMACAR‐NK cellsNK‐92immunotherapymultiple myeloma

Substanzen

B-Cell Maturation AntigenReceptors, Chimeric AntigenTNFRSF17 protein, humanInterferon-gammaCytokines

Autor:innen und Institutionen

  • Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University (TMU), Tehran, Iran.
  • Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Masoud Soleimani

Förderung

  • Tarbiat Modares University

Zitieren

APA

Divsalar, B., Kiani, J., Abroun, S., & Soleimani, M. (2026). Anti‐ BCMA CAR ‐ NK Cells Reveal Enhanced Cytolytic and Secretory Responses Against Myeloma Cells. APMIS. https://doi.org/10.1111/apm.70256

Vancouver

Divsalar B, Kiani J, Abroun S, Soleimani M. Anti‐ BCMA CAR ‐ NK Cells Reveal Enhanced Cytolytic and Secretory Responses Against Myeloma Cells. APMIS. 2026. doi:10.1111/apm.70256

BibTeX
@article{Divsalar2026,
  author = {Divsalar, Bita and Kiani, Jaffar and Abroun, Saeid and Soleimani, Masoud},
  title = {Anti‐ BCMA CAR ‐ NK Cells Reveal Enhanced Cytolytic and Secretory Responses Against Myeloma Cells},
  journal = {APMIS},
  year = {2026},
  doi = {10.1111/apm.70256}
}
Kostenlos starten →